{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.0","upperLimit":"97.2","value":"77.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":": Evaluate the overall response rate of patients receiving therapy. Patients are considered as having a response if their overall response is Partial Response or better. The percentage of patients achieving this and the exact 95% confidence interval will be calculated. Responses will be defined using the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC).","dispersionType":"95% Confidence Interval","groups":[{"description":"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.\n\nMAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncarfilzomib: Given IV\n\ndexamethasone: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Carfilzomib, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"All patients receiving at least one dose of study drug and having at least one evaluable post-baseline visit","reportingStatus":"POSTED","timeFrame":"At 32 weeks","title":"Overall Response Rate (ORR) After 8 Courses of Treatment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}